Gastrinoma

Radionucleotide therapy should be used for tumors exhibiting radiotracer uptake, either after surgery to eradicate microscopic residual disease or subsequently if conventional treatment or biotherapy fail. The priority should be to maintain quality of life, particularly because patients with disseminated disease may have prolonged survival.